Mei Ri Jing Ji Xin Wen·2025-08-05 08:57Core Viewpoint - Xinhua Pharmaceutical's subsidiary, Xinda Pharmaceutical, has received approval for Finasteride tablets, which are indicated for the treatment of benign prostatic hyperplasia (BPH) and prevention of urinary system events, enhancing the company's product portfolio and market opportunities [2] Group 1: Product Approval and Market Impact - Xinda Pharmaceutical has been granted a drug registration certificate for Finasteride tablets by the National Medical Products Administration [2] - The Finasteride tablets are classified as a Category B drug under the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [2] - The estimated sales revenue for Finasteride tablets in Chinese public medical institutions is approximately RMB 1.45 billion in 2024 [2] Group 2: Strategic Implications - The approval of Finasteride tablets is expected to enrich the company's product line and explore new market segments [2] - The pharmaceutical sales business is subject to uncertainties due to potential changes in domestic pharmaceutical policies and market conditions [2]